The Supreme Court asks the Union to ensure affordable medications for patients with rare diseases
Last Updated on February 25, 2025 by NewsDesk SLC
The Supreme Court yesterday (February 24) maintained the order of the High Court of Kerala that ordered the union to obtain medications worth 18 Lakh for the treatment of the rare spinal muscular atrophy as a unique measure. The court also asked the union to explore a possible appeal to subsidize drugs.
The Bench of CJI Sanjiv Khanna and Judge Sanjay Kumar were listening to a rare disease with a rare disease. – Spinal muscle atrophy would not be equivalent to a preceding union for other patients in a similar way. The High court of Kerala was dealing with the supplication of a 24 -year -old muscular atrophy (SMA), against excess medicine that save lives, Risdiplam.
In particular, the Apex court is currently seized from many requests presented by parents of children who suffer from muscle dystrophy (a rare disease) seeking a policy for the free treatment of the disease. On December 9, 2024 he also maintained the order of the High Court of Delhi that led the elimination of a ₹ 50 Lakhs limit for the treatment of rare diseases that declares that it is flexible.
Yesterday, the Court when issuing a notice to the current SLP filed by the union, remained with the order of the Superior Court of Kerala.
“Returnable issuance notice in the week that begins on April 17, 2025 ….. until the next hearing date, there will be a suspension of the order of the contested sentence. “The defendant lawyer reported that Pakistan and China negotiated to reduce the price of medicines used in the treatment of rare diseases.
The ICC also asked the parties to explore the possibility of participating directly with the drug manufacturing company in question. Said in order: “We would also ask the petitioners and the union of India to communicate with the company that manufactures these medications to allow the treatment of patients suffering from this disease.”
The court was informed that 900 individuals suffered similarly due to these rare diseases. The CJI verbally expressed the need for the union to explore international negotiations for a more affordable treatment:
Discover something, there are 900 people suffering from this disease, the government can also negotiate; I don’t know how many doses are required, but maybe the government. You have to negotiate and say please do it, we continue paying so much money, but take 50 Lakhs throughout the dose, throughout life.
However, the union’s lawyer pointed out that these doses are made to measure according to the patient requirement monthly or bimilosa. Consequently, the bank allowed respondents to place in record details of the other countries that managed to obtain subsidized medicines.
